Futibatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion
TAS-120-203
Phase 2 small_molecule active
Quick answer
Futibatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion for Advanced or Metastatic Urothelial Carcinoma is a Phase 2 program (small_molecule) at Taiho Pharma Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Taiho Pharma Netherlands B.V.
- Indication
- Advanced or Metastatic Urothelial Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active